Sol-Gel Technologies Ltd. (NASDAQ:SLGL) Short Interest Update

Sol-Gel Technologies Ltd. (NASDAQ:SLGL) was the target of a large decrease in short interest during the month of January. As of January 31st, there was short interest totalling 47,700 shares, a decrease of 77.2% from the January 15th total of 209,500 shares. Approximately 0.7% of the shares of the stock are sold short. Based on an average trading volume of 507,400 shares, the days-to-cover ratio is presently 0.1 days.

Sol-Gel Technologies Price Performance

NASDAQ SLGL traded down $0.02 during trading on Wednesday, reaching $0.60. The company’s stock had a trading volume of 59,900 shares, compared to its average volume of 270,157. The stock has a market capitalization of $16.80 million, a PE ratio of -1.77 and a beta of 1.31. The firm has a fifty day moving average of $0.85 and a 200 day moving average of $0.68. Sol-Gel Technologies has a one year low of $0.33 and a one year high of $1.65.

Hedge Funds Weigh In On Sol-Gel Technologies

A hedge fund recently bought a new stake in Sol-Gel Technologies stock. Raymond James Financial Inc. acquired a new stake in shares of Sol-Gel Technologies Ltd. (NASDAQ:SLGL) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor acquired 108,990 shares of the company’s stock, valued at approximately $101,000. Raymond James Financial Inc. owned about 0.39% of Sol-Gel Technologies at the end of the most recent quarter. 26.18% of the stock is owned by institutional investors.

About Sol-Gel Technologies

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc, develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea.